ABL1 and prostate carcinoma: Considering the magnitude of the increase in tumor progression and metastasis we observed in our prostate cancer model, it will be important to determine the cellular contexts in which Abl kinase inhibition may have paradoxical tumor promoting effects, since imatinib and other kinase inhibitors that cross-inhibit Abl are in clinical use.